Antidote Therapeutics
Antidote Therapeutics is a biopharmaceutical company developing first-in-class nicotine-blocking therapies to treat diseases caused or worsened by nicotine. Their mission is to develop innovative treatments that neutralize or eliminate nicotine in the blood, thereby reducing its harmful effects and addictiveness. They focus on orphan vascular diseases such as Buerger’s Disease and Critical Limb Ischemia, aiming to provide new treatment options for patients with severe peripheral arterial disease related to smoking. Their vision includes expanding the use of their products to other smoking-related illnesses and aiding smoking cessation.
Industries
Nr. of Employees
small (1-50)
Antidote Therapeutics
1500 Fannie Dorsey Road, Sykesville, MD 21784 USA
Patents
Products
Anti-ligand monoclonal antibody therapeutic (development-stage)
A fully human monoclonal antibody therapeutic that binds a circulating small-molecule ligand with high affinity and selectivity, sequestering the ligand in blood and reducing its distribution to target organs in preclinical models.
Small-molecule‑degrading enzyme therapeutic (lead optimization)
A protein enzyme therapeutic that metabolizes a specific small molecule in the bloodstream, rapidly reducing blood and brain exposure; undergoing optimization for catalytic efficiency, circulating half-life, and reduced immunogenicity.
Anti-ligand monoclonal antibody therapeutic (development-stage)
A fully human monoclonal antibody therapeutic that binds a circulating small-molecule ligand with high affinity and selectivity, sequestering the ligand in blood and reducing its distribution to target organs in preclinical models.
Small-molecule‑degrading enzyme therapeutic (lead optimization)
A protein enzyme therapeutic that metabolizes a specific small molecule in the bloodstream, rapidly reducing blood and brain exposure; undergoing optimization for catalytic efficiency, circulating half-life, and reduced immunogenicity.
Services
Joint R&D programs and sponsored research agreements to advance discovery, protein/enzyme optimization, and IND-enabling studies through academic and industry collaborators.
Development and transfer of biologic manufacturing processes and production of material for IND-enabling studies and clinical trials through contract manufacturing partnerships.
Joint R&D programs and sponsored research agreements to advance discovery, protein/enzyme optimization, and IND-enabling studies through academic and industry collaborators.
Development and transfer of biologic manufacturing processes and production of material for IND-enabling studies and clinical trials through contract manufacturing partnerships.
Expertise Areas
- Biologics discovery and development
- Enzyme therapeutics and optimization
- Protein engineering and directed evolution
- Preclinical pharmacology and toxicology
Key Technologies
- Isolation of human monoclonal antibodies from B cells
- Ligand‑binding antibody therapeutics
- Small-molecule‑degrading enzyme therapeutics
- Directed evolution and mutational optimization
News & Updates
FDA grants orphan drug status for ATI-1013, a monoclonal antibody for Buerger’s Disease, a rare vascular disorder caused by smoking.
Preclinical studies demonstrate increased activity, longer half-life, and reduced immunogenicity of NicA2 enzyme.
Study shows NicA2 reduces nicotine levels in blood and brain, and extinguishes nicotine self-administration in rats.
Antidote Therapeutics is developing a drug to diminish nicotine effects and aid in smoking cessation.
Antidote Therapeutics was recognized for its innovative deep tech solutions.
FDA grants orphan drug status for ATI-1013, a monoclonal antibody for Buerger’s Disease, a rare vascular disorder caused by smoking.
Preclinical studies demonstrate increased activity, longer half-life, and reduced immunogenicity of NicA2 enzyme.
Study shows NicA2 reduces nicotine levels in blood and brain, and extinguishes nicotine self-administration in rats.
Antidote Therapeutics is developing a drug to diminish nicotine effects and aid in smoking cessation.
Antidote Therapeutics was recognized for its innovative deep tech solutions.